Comprehensive plasma metabolomics profiling develops diagnostic biomarkers of obstructive hypertrophic cardiomyopathy
Abstract Hypertrophic cardiomyopathy (HCM) is the common cause of sudden cardiac death in young people and is characterized by cardiac hypertrophy. Non-HCM caused left ventricular hypertrophy (LVH) is more common in the population, especially in people with hypertension, obesity, and diabetes. In or...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-04-01
|
| Series: | Biomarker Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40364-025-00768-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849765426114854912 |
|---|---|
| author | Hao Cui Yifan Wang Xiumeng Hua Jing Han Han Mo Shun Liu Hongmei Wang Siyuan Huang Yiqi Zhao Xiao Chen Qian Zhao Hao Jia Yuan Chang Jiangping Song |
| author_facet | Hao Cui Yifan Wang Xiumeng Hua Jing Han Han Mo Shun Liu Hongmei Wang Siyuan Huang Yiqi Zhao Xiao Chen Qian Zhao Hao Jia Yuan Chang Jiangping Song |
| author_sort | Hao Cui |
| collection | DOAJ |
| description | Abstract Hypertrophic cardiomyopathy (HCM) is the common cause of sudden cardiac death in young people and is characterized by cardiac hypertrophy. Non-HCM caused left ventricular hypertrophy (LVH) is more common in the population, especially in people with hypertension, obesity, and diabetes. In order to identify high-risk populations, a screening technique that can rapidly differentiate between HCM and LVH patients should be developed. Plasma metabolomics may help develop useful biomarkers for the disease diagnosis. We performed a comprehensive plasma metabolomic analysis on a total of 720 individuals, included 441 HCM patients, 160 LVH patients, and 119 normal controls (NC) (derivation cohort = 368, validation cohort = 352). Orthogonal partial least squares discriminant analysis (OPLS-DA) was used to construct discriminant models based on metabolomics, and the result showed significant changes in plasma metabolic profiling among the HCM, LVH, and NC. The prospective diagnostic biomarkers for HCM patients have been examined using variable importance in projection, fold change, and FDR. Acylcarnitines efficiently distinguished HCM and LVH patients, with a C14:0-carnitine AUC of 0.937 shown by the reiver operator characteristic (ROC) curve analysis. The biomarkers for the diagnosis of HCM patients was verified in another independent validation cohort. This study is the largest plasma metabolomics analysis of Chinese Han patients with HCM, finding biomarkers that can be used to distinguish between HCM from LVH patients. These results highlight the great potential value of plasma metabolic profiling analysis on HCM diagnoses. |
| format | Article |
| id | doaj-art-aa8b5b887d684ea68235c4b48ccff49b |
| institution | DOAJ |
| issn | 2050-7771 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | BMC |
| record_format | Article |
| series | Biomarker Research |
| spelling | doaj-art-aa8b5b887d684ea68235c4b48ccff49b2025-08-20T03:04:51ZengBMCBiomarker Research2050-77712025-04-011311510.1186/s40364-025-00768-0Comprehensive plasma metabolomics profiling develops diagnostic biomarkers of obstructive hypertrophic cardiomyopathyHao Cui0Yifan Wang1Xiumeng Hua2Jing Han3Han Mo4Shun Liu5Hongmei Wang6Siyuan Huang7Yiqi Zhao8Xiao Chen9Qian Zhao10Hao Jia11Yuan Chang12Jiangping Song13State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical CollegeShenzhen Key Laboratory of Cardiovascular Disease, Fuwai Hospital Chinese Academy of Medical SciencesState Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical CollegeAbstract Hypertrophic cardiomyopathy (HCM) is the common cause of sudden cardiac death in young people and is characterized by cardiac hypertrophy. Non-HCM caused left ventricular hypertrophy (LVH) is more common in the population, especially in people with hypertension, obesity, and diabetes. In order to identify high-risk populations, a screening technique that can rapidly differentiate between HCM and LVH patients should be developed. Plasma metabolomics may help develop useful biomarkers for the disease diagnosis. We performed a comprehensive plasma metabolomic analysis on a total of 720 individuals, included 441 HCM patients, 160 LVH patients, and 119 normal controls (NC) (derivation cohort = 368, validation cohort = 352). Orthogonal partial least squares discriminant analysis (OPLS-DA) was used to construct discriminant models based on metabolomics, and the result showed significant changes in plasma metabolic profiling among the HCM, LVH, and NC. The prospective diagnostic biomarkers for HCM patients have been examined using variable importance in projection, fold change, and FDR. Acylcarnitines efficiently distinguished HCM and LVH patients, with a C14:0-carnitine AUC of 0.937 shown by the reiver operator characteristic (ROC) curve analysis. The biomarkers for the diagnosis of HCM patients was verified in another independent validation cohort. This study is the largest plasma metabolomics analysis of Chinese Han patients with HCM, finding biomarkers that can be used to distinguish between HCM from LVH patients. These results highlight the great potential value of plasma metabolic profiling analysis on HCM diagnoses.https://doi.org/10.1186/s40364-025-00768-0Hypertrophic cardiomyopathyLeft ventricular hypertrophyBiomarkerMetabolomicsDiagnosis |
| spellingShingle | Hao Cui Yifan Wang Xiumeng Hua Jing Han Han Mo Shun Liu Hongmei Wang Siyuan Huang Yiqi Zhao Xiao Chen Qian Zhao Hao Jia Yuan Chang Jiangping Song Comprehensive plasma metabolomics profiling develops diagnostic biomarkers of obstructive hypertrophic cardiomyopathy Biomarker Research Hypertrophic cardiomyopathy Left ventricular hypertrophy Biomarker Metabolomics Diagnosis |
| title | Comprehensive plasma metabolomics profiling develops diagnostic biomarkers of obstructive hypertrophic cardiomyopathy |
| title_full | Comprehensive plasma metabolomics profiling develops diagnostic biomarkers of obstructive hypertrophic cardiomyopathy |
| title_fullStr | Comprehensive plasma metabolomics profiling develops diagnostic biomarkers of obstructive hypertrophic cardiomyopathy |
| title_full_unstemmed | Comprehensive plasma metabolomics profiling develops diagnostic biomarkers of obstructive hypertrophic cardiomyopathy |
| title_short | Comprehensive plasma metabolomics profiling develops diagnostic biomarkers of obstructive hypertrophic cardiomyopathy |
| title_sort | comprehensive plasma metabolomics profiling develops diagnostic biomarkers of obstructive hypertrophic cardiomyopathy |
| topic | Hypertrophic cardiomyopathy Left ventricular hypertrophy Biomarker Metabolomics Diagnosis |
| url | https://doi.org/10.1186/s40364-025-00768-0 |
| work_keys_str_mv | AT haocui comprehensiveplasmametabolomicsprofilingdevelopsdiagnosticbiomarkersofobstructivehypertrophiccardiomyopathy AT yifanwang comprehensiveplasmametabolomicsprofilingdevelopsdiagnosticbiomarkersofobstructivehypertrophiccardiomyopathy AT xiumenghua comprehensiveplasmametabolomicsprofilingdevelopsdiagnosticbiomarkersofobstructivehypertrophiccardiomyopathy AT jinghan comprehensiveplasmametabolomicsprofilingdevelopsdiagnosticbiomarkersofobstructivehypertrophiccardiomyopathy AT hanmo comprehensiveplasmametabolomicsprofilingdevelopsdiagnosticbiomarkersofobstructivehypertrophiccardiomyopathy AT shunliu comprehensiveplasmametabolomicsprofilingdevelopsdiagnosticbiomarkersofobstructivehypertrophiccardiomyopathy AT hongmeiwang comprehensiveplasmametabolomicsprofilingdevelopsdiagnosticbiomarkersofobstructivehypertrophiccardiomyopathy AT siyuanhuang comprehensiveplasmametabolomicsprofilingdevelopsdiagnosticbiomarkersofobstructivehypertrophiccardiomyopathy AT yiqizhao comprehensiveplasmametabolomicsprofilingdevelopsdiagnosticbiomarkersofobstructivehypertrophiccardiomyopathy AT xiaochen comprehensiveplasmametabolomicsprofilingdevelopsdiagnosticbiomarkersofobstructivehypertrophiccardiomyopathy AT qianzhao comprehensiveplasmametabolomicsprofilingdevelopsdiagnosticbiomarkersofobstructivehypertrophiccardiomyopathy AT haojia comprehensiveplasmametabolomicsprofilingdevelopsdiagnosticbiomarkersofobstructivehypertrophiccardiomyopathy AT yuanchang comprehensiveplasmametabolomicsprofilingdevelopsdiagnosticbiomarkersofobstructivehypertrophiccardiomyopathy AT jiangpingsong comprehensiveplasmametabolomicsprofilingdevelopsdiagnosticbiomarkersofobstructivehypertrophiccardiomyopathy |